Business
Hikma in-licenses proprietary injectable product
Hikma in-licenses proprietary injectable product.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n \nRNS Number : 4856M Hikma Pharmaceuticals Plc 17 August 2011 \n \n\n \n \nPRESS RELEASE \n \n \nHikma in-licenses major proprietary injectable product Ferinject® for the MENA region\n\nLondon, 17 July, 2011: Hikma Pharmaceuticals (LSE: HIK) (NASDAQ Dubai: HIK) (\"Hikma\"), the fast growing pharmaceutical company, today announces that its wholly-owned subsidiary Hikma Pharmaceuticals Ltd. has entered into a licensing and distribution agreement with Vifor Pharma, a wholly-owned subsidiary of the Galenica Group, under which Hikma will market Ferinject®, Vifor Pharma's innovative treatment for iron deficiency, in the Middle East and North African region (\"MENA\"). The agreement will leverage Hikma's local presence, regional marketing and regulatory expertise, allowing Hikma to maximise the potential of one of the world's fastest-growing markets for iron deficiency products.\n\nThe agreement covers Algeria, Egypt, Iraq, Jordan, Lebanon, Libya, Morocco, South Sudan, Sudan, Syria, Tunisia and Yemen. Patients in these countries will gain access to Ferinject®, an efficacious, well tolerated and convenient treatment for iron deficiency. Hikma, with over 1,600 sales and marketing staff in the region, will receive exclusive rights to market and distribute a product that complements its portfolio of prescription pharmaceuticals. Vifor Pharma, one of the world's leaders in the treatment of iron deficiency, will see Ferinject® registered and brought to market far more quickly than would otherwise be possible.\n\n\"This collaboration is great news for Vifor Pharma. It is also very good news for all patients suffering from iron deficiency in the MENA region. These patients will soon have access to a new and much-needed therapeutic option,\" said Dr. David Ebsworth, CEO of Vifor Pharma. \"I am delighted that Hikma - a company with great expertise and standing - shares our view of the potential of Ferinj...